Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Pittsburgh
University of Colorado, Denver
SCRI Development Innovations, LLC
Gustave Roussy, Cancer Campus, Grand Paris
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
University Medical Center Groningen
University of California, San Francisco
Omico
The Netherlands Cancer Institute
Washington University School of Medicine
Yonsei University